Table 1.

International Consensus Classification 2022 for myeloproliferative neoplasms and associated cardiovascular risk factors and complications.

MPNs	Major Criteria	Minor Criteria	Cardiovascular Risk Factors and Complications	References
PV	hemoglobin: >16.5 g/dL in men; >16.0 g/dL in women; hematocrit: >49% in men and >48% in women JAK2 V617F or JAK2 exon 12 mutation	EPO concentrations lower than normal	Hypertension (40–70%) [147] Diabetes melitius (7–16%) [148] Obesity (7.5%) and smoking (5–10%) [38] Myocardial infarction (30%) [149] Stroke (25%) [149] Peripheral arterial thrombosis (20%) [149]	[38,147,148,149,150,151]
ET	Platelet count ≥ 450 × 109/L JAK2, CALR, or MPL mutation	Exclusion of secondary causes of platelet number increase	Thrombotic risk before diagnostic 18% [152] Each cardiovascular risk increases the thrombotic risk [153]: No CV risk (14%) 1 CV risk (16%) More than 1 CV risk (29%)	[150,151,152,153]
PMF	High-grade reticulin fibrosis (2 or 3 grade) JAK2, CALR, or MPL mutation	Secondary anemia excluded Leukocytosis ≥ 11 × 109/L Enlarged spleen LDH levels raised above normal interval Leucoerythroblastosis	Thrombotic events [154]: Myocardial infarction (9.5%) Stroke (2.3%) Venous thromboembolism (4.5%) Splanchnic thrombosis (0.6%)	[150,151,154]

JAK2—Janus kinase 2; MPL—myeloproliferative leukemia protein; CALR—calreticulin; EPO—erythropoietin; LDH–lactate dehydrogenase.